Kesavan Ramasamy
Overview
Explore the profile of Kesavan Ramasamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar S, Ramasamy K, Natarajan H, Venkatraman S, Eriyat V, Kundra P
Pharmacogenomics
. 2024 Nov;
25(14-15):595-603.
PMID: 39563600
Aim: The study aimed to examine the association of two selected candidate SNPs rs2242480 (CYP3A4) and rs1045642 (ABCB1) with metabolic ratio of plasma norfentanyl to fentanyl concentrations in patients undergoing...
2.
Deva R, Rajendran P, Ramasamy S, Selvan S, Ramasamy K
Drug Metab Pers Ther
. 2023 Dec;
39(1):21-26.
PMID: 38097396
Objectives: Azathioprine (AZA) is an effective immunosuppressant commonly used for malignancy and immune-mediated disorders. The association between genetic polymorphisms and AZA-induced adverse effects has not been elucidated. Hence this study...
3.
Venkatraman S, Ramasamy K, Nair P
Indian J Pharmacol
. 2023 Aug;
55(3):149-154.
PMID: 37555408
Objectives: Carbamazepine (CBZ), an anti-seizure drug, is widely prescribed for the management of focal seizures. At a given therapeutic dose, CBZ exhibits marked interindividual variation in the plasma CBZ levels....
4.
Venkatraman S, Ramasamy K, Nair P, Rajendran P
Drug Metab Pers Ther
. 2023 Feb;
38(2):191-197.
PMID: 36853909
Objectives: Carbamazepine (CBZ) is a first-line antiseizure drug used for focal onset seizures. It exhibits inter-individual variability in plasma carbamazepine levels and there are both genetic and non-genetic factors having...
5.
Devanathan R, Alladi C, Ravichandran M, Ramasamy K, Uppugunduri C
Pharmacogenomics
. 2023 Feb;
24(3):123-129.
PMID: 36786192
The Indo-Swiss symposium on pharmacogenomic strategies for the implementation of personalized medicine was conducted as part of the Jawaharlal Institute of Postgraduate Medical Education and Research Integrated Pharmacogenomics Program in...
6.
Priyadharsini R, Ramasamy K, Amarendar S
J Family Med Prim Care
. 2022 Mar;
11(1):74-78.
PMID: 35309648
Context: Rational drug use has a great role of influence in health care. The fact sheet given by the World Health Organization (WHO) shows that around 50% of the drugs...
7.
Meena D, Jayanthi M, Ramasamy K, Thulasingam M
Cureus
. 2022 Feb;
14(1):e21389.
PMID: 35198298
Background Large amounts of medicines are wasted during procurement, storage, distribution, and utilization. Proper procurement, storage, dispensing, and documentation of medicines are important aspects of pharmacy management. The World Health...
8.
Meena D, Jayanthi M, Ramasamy K, T M
Cureus
. 2021 Dec;
13(11):e19419.
PMID: 34926013
Introduction The supply of essential medicines is one of the vital components of primary health care. One of the important objectives of Indian health policy is to provide all the...
9.
Meena D, Mathaiyan J, Thulasingam M, Ramasamy K
Br J Clin Pharmacol
. 2021 Dec;
88(5):2315-2326.
PMID: 34859476
Objective: To assess medicine use based on World Health Organization (WHO) core drug-use indicators in selected public health facilities of the South Indian Union Territory. Methods: A prospective cross-sectional study...
10.
Thakkar D, Ramasamy K, Adithan S, Selvarajan S, Dubashi B
J Cancer Res Ther
. 2021 Jun;
17(2):443-449.
PMID: 34121690
Aim: Bleomycin, etoposide, and cisplatin (BEP) regimen is the standard treatment for germ-cell tumors (GCTs). Bleomycin-induced pulmonary toxicity (BPT) is fatal and dose-limiting toxicity associated with this regimen. In this...